THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)
The GEM Listing Committee of the Stock Exchange of Hong Kong Limited
censures Northeast Tiger Pharmaceutical Company Limited (the "Company")
for breaching the then Rules 20.24 and 20.50 of the GEM Listing Rules and
executive directors Mr. Xu Zhe (also Chairman of the Company), Ms. Du Li Hua,
Mr. Leng Zhan Ren and Mr. Liu Xiao Hong (the "Relevant Directors")
for breaching the undertaking as directors of the Company
At a meeting held on2 December 2004, the GEM Listing Committee considered the facts and circumstances of the following three connected transactions between the Company and Jilin Far East Pharmaceutical Holdings Company Limited ("FE Holdings"), a substantial shareholder of the Company:
According to the then Rule 20.24 of the GEM Listing Rules, a transaction on normal commercial terms with a connected person where the total consideration or value was less than the higher of: i) HK$10M; or ii) 3% of the net tangible assets of the listed issuer, would be subject to the reporting and announcement requirements. The relevant net tangible assets of the Company were about RMB81.7 million. The Company had reported CT1 in its annual report for the year ended 31 December 2002 ("Annual Report 2002") but had neither made the timely announcement (which was subsequently made on 13 March 2003) nor informed the Exchange at an early stage.
According to the then Rule 20.50 of the GEM Listing Rules, any transaction involving a connected person and financial assistance which was not exempted would be subject to the reporting, announcement and independent shareholders' approval requirements. Such transactions included the grant of financial assistance which was not in the ordinary and usual course of business, and not on normal commercial terms. The Company had reported CT2 and CT3 in Annual Report 2002 but had neither made the timely announcement (which was subsequently made on13 March 2003) nor informed the Exchange at an early stage. Nor had it sought independent shareholders' approval.
The GEM Listing Committee concluded that:
Accordingly, the Company and the Relevant Directors are publicly censured for their respective breaches mentioned above.
"The compliance requirements as stipulated in the relevant GEM Listing Rules are intended to ensure that the interests of shareholders as a whole are taken into account when listed issuers enter into transactions with connected parties. Accordingly, listed issuers should ensure that they have adequate procedures in place in order to satisfy such compliance requirements." Head of Listing, Richard Williams said.